Control strategies
Nitrosamine control strategies in pharmaceutical manufacturing focus on preventing their formation by minimising precursor availability, avoiding conditions that promote nitrosation, and strengthening purification and material controls. Measures such as enhanced filtration, distillation, targeted chemical treatments and strict supplier qualification are used to reduce risk, while analytical testing of raw materials and intermediates plays a key role in preventing the introduction or build-up of nitrosamines downstream.
Nitrosamine control is most effective when it starts at the process-design stage, rather than relying only on end-stage purification or analytical testing. 9 Each synthetic step needs to be evaluated for the potential conditions for nitrosamine formation, especially when NH-containing substrates are exposed to nitrosating species, such as nitrosonium ion carriers([ NO +]). This is particularly important for API synthesis routes that involve secondary amines, azide chemistry, acidic conditions, or amine-containing reagents and solvents.
Case study: Sitagliptin
A nitrosamine risk assessment of the sitagliptin hydrochloride monohydrate manufacturing process was identified when using the conventional tetrazoleforming step as a critical source of potential Nitroso Drug Substances- Related Impurities( NDSRI) formation. 4
The original Finnegan-type procedure employed sodium azide and ammonium chloride in DMF at 80 ° C, conditions that could generate nitrosating species through azide hydrolysis and ammonium azide formation. Because the triazolopyrazine intermediate( TTP) contains a secondary aromatic amine susceptible to nitrosation under acidic conditions, the process was assessed as high risk, with predicted NTTP levels of 50 – 200 ng / g, exceeding the acceptable intake threshold( Figure 5).
Risk evaluation further indicated that downstream purification alone would not reliably prevent impurity formation. To mitigate this risk, three alternative tetrazole synthesis strategies were evaluated:
• A continuous-flow process using silyl azide and primary amine substrates, eliminating sodium azide
• Substitution of ammonium chloride with benzylamine hydrochloride, while retaining sodium azide
• A zinc-catalysed aqueous cycloaddition
The continuous-flow approach was selected because it completely removed the identified nitrosation pathway, reduced reaction times from hours to minutes and was compatible with sitagliptin-related substrates.
The optimised process involved continuous injection of the primary amine substrate and silyl azide into a flow reactor operated at 60 ° C with a residence time of 5 – 10 min, followed by direct quenching and tetrazole isolation by crystallisation. Additional controls included maintaining pH > 6.0, implementing crystallisation conditions providing a tenfold solubility purge of
Figure 4- Suggested dealkylation & nitrosation pathway leading to NCMA formation nitrosamines, routine LC-MS / MS analysis with a limit of quantitation of ≤0.03 ppm and raw material qualification for nitrite levels below 0.1 ppb.
Implementation of the new process substantially improved performance: yield increased from 72 % to 85 %, reaction time decreased from 4 – 6 hours to 5 – 10 minutes, nitrosamine NTTP levels fell from 120 ng / g to below the analytical detection limit(< 0.03 ppm), solvent consumption decreased by 47 % and overall process risk was reduced from high to low. The principal trade-off was the capital investment required for continuous flow equipment( approximately $ 250,000).
The regulatory outcome was favourable. The FDA pre-approval inspection passed with no nitrosaminerelated observations. API specification removed the NTTP limit since the impurity was not detectable. Drug product approval was granted without nitrosamine mitigation requirements and $ 5-10 million in post-approval remediation costs were avoided. Sixmonth stability studies at 40 ° C confirmed no increase in NTTP. Consistent results were obtained across four manufacturing sites using the process.
This work demonstrates that investigating alternative processes is essential for nitrosamine control. By replacing the traditional azide-based batch process with continuous flow from primary amines, nitrosamine formation was eliminated.
Analytical testing
Analytical testing is the cornerstone of nitrosamine risk assessment and control, requiring methods capable of detecting nitrosamines impurities at sub-ppb levels below compoundspecific acceptable intake thresholds( 18 – 1,500 ng / day). A pharmaceutical case study demonstrated that interlaboratory variability in nitrosamine recovery( 45 – 95 %) was driven primarily by sample preparation differences, not chromatographic or detection performance.
Sample preparation is the main source of variability and risk in nitrosamine analysis. 1 Mechanical operations
28 SPECIALITY CHEMICALS MAGAZINE ESTABLISHED 1981